Genetic Mutation Analysis and Interpretation

Genetic mutation analysis and interpretation is the area of molecular pathology concerned with detecting changes in DNA sequence and dosage and then deciding what those changes mean — whether a variant is pathogenic, benign, or of uncertain significance, and whether it is inherited or acquired. It links the technical output of sequencing and genomic assays to a structured, evidence-weighted judgement about biological and clinical significance.

Definition

Genetic mutation analysis and interpretation is the systematic detection and evidence-based classification of DNA sequence and structural variants, assigning each variant a significance category (for example pathogenic, likely pathogenic, uncertain, likely benign, benign) using population, computational, functional, and segregation evidence.

Scope

The area orients the reader across the main interpretive problems: how variants are classified against standardised frameworks, how mechanism (loss versus gain of function) shapes interpretation, how large copy-number and structural changes are handled, how variants in splicing and regulatory regions are assessed, and how somatic (acquired) variants are distinguished from germline (inherited) ones. It is a reference overview; the detailed essentials live in the topic entries beneath it.

Sub-topics

• copy number variants and structural variants
• loss of function and gain of function mutations
• sequence variant classification frameworks
• somatic vs germline mutation assessment
• splicing variants and regulatory mutations

Core questions

• What kinds of DNA change exist, and how are they detected and described in a standardised way?
• How is the clinical or biological significance of a variant established from converging lines of evidence?
• How does the molecular mechanism of a variant inform its interpretation?
• How are inherited (germline) and acquired (somatic) variants told apart, and why does the distinction matter?

Key concepts

• Sequence variant
• Pathogenicity classification
• Variant of uncertain significance
• Loss-of-function and gain-of-function
• Copy-number and structural variation
• Somatic versus germline origin
• Evidence-based variant assessment

Mechanisms

Interpretation proceeds by gathering multiple, partly independent lines of evidence about a variant and combining them into a category. Population frequency databases indicate whether a variant is too common to cause a rare disease; computational predictors estimate impact on protein or splicing; functional studies test consequence experimentally; and family segregation links the variant to phenotype. The ACMG/AMP framework for germline variants and the AMP/ASCO/CAP framework for somatic variants formalise how these strands are weighted into a final classification. Mechanism matters throughout: a frameshift in a gene that acts through haploinsufficiency is interpreted differently from a missense change in an oncogene that acts through activation, as summarised in reviews of variant prioritisation and cancer genomes.

Clinical relevance

Variant interpretation underpins much of genomic medicine, from diagnosing Mendelian disease to characterising tumours, and reading interpretation reports critically is part of laboratory and clinical practice. This area describes how significance is reasoned about and reported; it explains the logic of classification frameworks and is not a substitute for individualised genetic counselling or treatment decisions.

Evidence & guidelines

Two consensus frameworks anchor practice: the 2015 ACMG/AMP standards for germline sequence variants (Richards et al., 2015) and the 2017 AMP/ASCO/CAP standards for somatic variants in cancer (Li et al., 2017). Methodological reviews describe how computational and population evidence feed variant prioritisation (Eilbeck et al., 2017), and surveys of cancer genome landscapes frame the somatic side of interpretation (Vogelstein et al., 2013).

History

Variant interpretation matured as sequencing scaled from single genes to exomes and genomes. Early ad hoc judgements gave way to structured criteria, consolidated for germline variants in the 2015 ACMG/AMP guideline and, for cancer, in the 2017 AMP/ASCO/CAP guideline; large population databases and computational predictors progressively strengthened the evidence base for these frameworks.

Seminal works

• richards-2015
• li-2017
• vogelstein-2013

Frequently asked questions

What does it mean to interpret a genetic variant?

It means combining evidence — population frequency, computational prediction, functional data, and inheritance pattern — to decide whether a DNA change is likely to cause disease, is harmless, or cannot yet be classified.

Why are so many variants labelled 'of uncertain significance'?

When the available evidence is insufficient or conflicting, classification frameworks deliberately place a variant in an uncertain category rather than overcalling it pathogenic or benign; reclassification can occur as more evidence accumulates.